Shots: Y-Biologics to receive ~$2M up front and eligible to receive ~$85M as development, regulatory, & commercialization milestones along with royalties on sales in the territory 3D Medicines will get an exclusive right to develop, manufacture, and commercialize YBL-013 in China with the expansion of collaboration in the US and other regions Both the companies […]Read More
Shots: Voyager retains full rights to the vectorization technology and novel vectorized Abs emerges from the collaboration and has the right to pursue vectorized Ab programs targeting tau and alpha-synuclein alone or in collaboration with another partner As per collaboration agreements, Voyager has received an upfront payment to perform research and preclinical development of vectorized […]Read More
Shots: AstraZeneca has completed its agreement with Allergan to recover the global rights to brazikumab (formerly MEDI2070). Both the companies have terminated their 2016 agreement and all rights to brazikumab, now returned to AstraZeneca Allergan to fund up to an agreed amount, estimated to be the total costs expected to be incurred by AstraZeneca until […]Read More
Shots: As per the amended agreement, Gilead will reduce the royalty rates of Momelotinib & eliminates milestone payments in exchange for becoming a stockholder in Sierra, following the closing of Sierra’s qualified financing. In Aug’2018, Sierra acquired Gilead’s Momelotinib for $3M up front, $195M milestones and royalties on sales Additionally, Sierra and Gilead Sciences would […]Read More
Shots: BioArctic to get $755M as total deal value (with upfront previously paid) and $50M milestone payments in addition to royalties on sales In 2016, AbbVie and BioArctic ($80M upfront) entered into a global collaboration to develop & commercialize BioArctic’s Alpha-Synuclein Ab Platform to treat Parkinson Disease BAN0805, a leading BioArctic’s Alpha-Synuclein Ab indicated for […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
